Hebatullah Samy Helmy

Hebatullah Samy Helmy

Auto-generated profile, based on publicly available information

Hebatullah Samy Helmy

Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2018 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
MSMuhammed A. Saad
Muhammed A. Saad
AEAyman E. El-Sahar
Ayman E. El-Sahar
RSRabab Sayed
Rabab Sayed
EEEman Elbaz
Eman Elbaz
HHHebatullah S. Helmy
Hebatullah S. Helmy
MSMahmoud Senousy
Mahmoud Senousy

1 September 2017 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
HHHebatullah Samy Helmy
Hebatullah Samy Helmy
AEAyman El-Sahar
Ayman El-Sahar
RSRabab Sayed
Rabab Sayed
Rehab ShammaRehab Shamma
Rehab Shamma
ASAlaa Hamed Salama
Alaa Hamed Salama
EEEman Elbaz
Eman Elbaz
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease treated by nonsteroidal anti-inflammatory drugs (NSAIDs) including lornoxicam (LX). Nanocarriers have been used to increase the efficacy and reduce the side effects of various drugs. The objective of the present study was to compare the therapeutic efficacy of systemic administration of lornoxicam-loaded nanomicellar formula (LX-NM) with that of free LX. Materials and methods: The LX-loaded mixed polymeric nanomicellar formula was prepared by direct equilibrium technique. Two rat models were used in the study: carrageenan-induced acute edema and Freund’s complete adjuvant (FCA)-induced chronic arthritis. Results: The inhibitory effect of LX-NM on carrageenan-induced edema was higher than free LX for the same dose (1.3 mg/kg, i.p.). LX-NM (0.325 mg/kg, i.p.) produced effects comparable to that of diclofenac, which served as a standard. In the FCA model, daily treatment with LX-NM (0.325 mg/kg, i.p.) starting on day 14 significantly reduced the percentage of edema and increased weight growth. However, the same dose of LX failed to confer any significant change. Additionally, LX-NM significantly attenuated the rise of tumor necrosis factor-α (TNF-α), interleukin-1β, prostaglandin E2, nuclear factor-κβ, malondialdehyde and nitric oxide serum levels. In contrast, LX failed to show any significant reduction in elevated serum biomarkers except for TNF-α. Conclusion: LX-NM is an alternative delivery system that is simply prepared at low costs. It showed a superior therapeutic efficacy against RA compared to free LX. Thus, LX-NM can be considered as a promising candidate for treatment of RA and similar inflammatory disorders.

23 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MSMahmoud Senousy
Mahmoud Senousy
HHHebatullah S. Helmy
Hebatullah S. Helmy
NFNevine Fathy
Nevine Fathy
OSOlfat Shaker
Olfat Shaker
GAGhada M. Ayeldeen
Ghada M. Ayeldeen
Single nucleotide polymorphisms (SNPs) in microRNA-target sites influence an individual’s risk and prognosis for autoimmune diseases. Myotubularin-related protein 3 (MTMR3), an autophagy-related gene, is a direct target of miR-181a. We investigated whether MTMR3 SNP rs12537 in the miR-181a-binding site is associated with the susceptibility and progression of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Overall, 94 patients with RA, 80 patients with SLE, and 104 healthy volunteers were recruited. Genotyping and expression analysis of circulating MTMR3 and miR-181a were performed by qPCR. The autophagic marker MAP1LC3B was measured by ELISA. The rs12537 minor homozygote (TT) genotype was a candidate risk factor of both RA and SLE. rs12537TT was associated with lower serum MTMR3 expression and higher LC3B levels than other genotypes in patients with both diseases. Serum miR-181a expression was higher in rs12537TT carriers than in other genotypes among SLE patients. Serum miR-181a and MTMR3 levels were inversely correlated in SLE but not in RA patients. rs12537TT and serum miR-181a were positively associated with disease severity in both diseases. Our results identify a novel role of rs12537 in the susceptibility and progression of RA and SLE, possibly through impacting the interaction between miR-181a and MTMR3 leading to increased autophagy.



1 February 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SEShaymaa M. El-Hady
Shaymaa M. El-Hady
MAMohamed H.H. AbouGhaly
Mohamed H.H. AbouGhaly
MEManal M. El-Ashmoony
Manal M. El-Ashmoony
HHHebatullah S. Helmy
Hebatullah S. Helmy
GGGazayerly El Gazayerly
Gazayerly El Gazayerly